Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics (Nasdaq: FDMT) has initiated its Phase 1/2 clinical trial for 4D-710, focusing on treating cystic fibrosis. The first patient has been dosed, marking a significant milestone for the company. This therapy aims to deliver CFTR expression to lung cells, potentially benefiting a wide range of cystic fibrosis patients, especially those unable to use existing treatments. The trial will assess safety, tolerability, and clinical activity, with around 18 patients expected to participate.
4D Molecular Therapeutics (Nasdaq: FDMT) reported 2021 financial results with total revenue of $18 million, up from $13.6 million in 2020, driven by a Roche collaboration. The company provided clinical data updates on three key programs, including 4D-310 for Fabry disease, showing promising results. Two additional programs have entered clinical development. The company ended 2021 with $315 million in cash, expected to fund operations through mid-2024. Despite increased R&D and G&A expenses, the net loss grew to $71.3 million from $56.7 million in 2020.
On February 22, 2022, 4D Molecular Therapeutics (Nasdaq: FDMT) announced the resignation of Professor David Schaffer, Ph.D., from its board of directors. This transition comes as the company evolves into a clinical-stage gene therapy firm, with five products currently in development. Professor Schaffer, who has served on the board since 2013, is taking up new roles at UC Berkeley, while emphasizing the company’s strengthened board with new independent directors. 4DMT aims to leverage its Therapeutic Vector Evolution platform for gene therapy innovations in ophthalmology, cardiology, and pulmonology.
4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference, scheduled for February 16, 2022, at 2:00 p.m. PT. The event will take the form of a fireside chat, and a live audio webcast will be accessible through the company’s website, with a replay available for two weeks post-event. 4DMT focuses on targeted gene therapies, currently developing five clinical-stage products for conditions including Fabry disease, wet AMD, and cystic fibrosis.
4D Molecular Therapeutics (Nasdaq: FDMT) has released interim data from its ongoing Phase 1/2 trial of 4D-310 for treating Fabry disease. The results indicate stable alpha-galactosidase A (AGA) activity among patients after discontinuing enzyme replacement therapy (ERT), with levels at 14-fold and 10-fold the normal range. Additionally, improvements were noted in cardiac imaging and quality-of-life scores. The trial aims to confirm safety and tolerability while assessing AGA activity and cardiac function.
4D Molecular Therapeutics (FDMT) announced updated interim clinical data for its 4D-310 Phase 1/2 trial aimed at treating Fabry disease. The presentation is scheduled for February 9, 2022, at the 18th Annual WORLD Symposium. 4D-310 utilizes the evolved C102 vector to deliver a functional GLA gene, potentially addressing unmet medical needs in Fabry patients suffering from life-threatening complications. The trial aims to demonstrate improved AGA enzyme levels, enhancing patients' quality of life and offering a novel therapeutic option beyond current enzyme replacement therapies.
4D Molecular Therapeutics (NASDAQ: FDMT) received Fast Track Designation from the FDA for its product candidate 4D-125 to treat inherited retinal dystrophies caused by defects in the RPGR gene. This designation aims to expedite development for serious conditions lacking approved treatments, providing 4DMT with closer communication with the FDA. 4D-125 is currently in a Phase 1/2 clinical trial to assess safety and clinical activity, catering to the urgent need for therapies for X-linked Retinitis Pigmentosa (XLRP), which affects an estimated 24,000 patients in the U.S. alone.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) has announced the dosing of the first patient in its Phase 1/2 clinical trial of 4D-150, a gene therapy for neovascular age-related macular degeneration (wet AMD). This milestone is part of a trial expected to enroll approximately 60 adults, evaluating 4D-150's safety and efficacy. 4D-150 aims to inhibit multiple angiogenic factors with a single low dose, addressing treatment burdens faced by patients. The therapy shows promise in providing long-term benefits after intravitreal administration, leveraging the company's proprietary R100 capsid technology.
4D Molecular Therapeutics (Nasdaq: FDMT) announced participation in a fireside chat at the Evercore ISI HealthCONx 2021 Conference on December 2, 2021, at 10:55 a.m. ET. This event offers insights into the company's advances in gene therapy.
A live audio webcast will be accessible via the Investors & Media section on the company's website, with a replay available for two weeks post-event. The company is focused on ophthalmology, cardiology, and pulmonology, and is developing five product candidates currently in clinical trials.
4D Molecular Therapeutics (Nasdaq: FDMT) reported its Q3 2021 financial results and operational milestones. The company showcased promising clinical data for three product candidates, including 4D-310 for Fabry disease, which demonstrated significantly enhanced AGA enzyme activity. The company raised approximately $111 million through a follow-on stock offering, strengthening its financial position with cash and equivalents totaling $227 million. However, total revenue decreased to $1.4 million, compared to $7.4 million in the same quarter last year, primarily due to a terminated collaboration.